MELBOURNE, Australia, Nov. 3 /PRNewswire-FirstCall/ -- Metabolic Pharmaceuticals Ltd / , today announced that Dr. Roland Scollay, Chief Executive Officer, will present at the Rodman & Renshaw Techvest Seventh Annual Healthcare Conference at 4:35 p.m. Eastern Time on Monday, November 7 at The New York Palace Hotel. During the presentation, Dr. Scollay will address the current status of Metabolic’s development program, including an explanation of its two high potential, clinical stage drugs - AOD9604 (obesity) and ACV1 (neuropathic pain).
The Company’s audio and slide presentation will be web cast live on November 7. A replay will be available one hour following the presentation and archived on the Company’s web site for 90 days. To access the live and replay presentations, visit the Investor Relations/Presentations section of the Metabolic Pharmaceuticals web site, http://www.metabolic.com.au.
Metabolic Pharmaceuticals Limited
Metabolic Pharmaceuticals Limited is a biotechnology company based in Melbourne, Australia. The Company was formed and listed on the Australian Stock Exchange in late 1998 and there are 254,410,601 shares on issue. Metabolic has approximately 23 employees. Our mission is to bring to the market innovative drugs which will improve people’s lives and return value to stakeholders. Metabolic currently has development programs aimed at treating obesity (AOD9604), and neuropathic pain (ACV1). AOD9604 has been through a Phase 2B clinical trial which showed good indications of efficacy and an excellent tolerability profile, and a further low dose study commenced in October 2005, with expected completion in January 2007. A Phase 1 clinical trial began for ACV1 in June 2005 and will be completed before the end of 2005. Metabolic also has discovery programs targeting type 2 diabetes and, in collaboration with Neuren Pharmaceutical Limited, nerve protection and regeneration. For more information, please visit the company’s website at http://www.metabolic.com.au.
Further information Company US Investors Roland Scollay, CEO Kathy Price, Tel: +61 3 9860 5700 The Global Consulting Group Email: roland.scollay@metabolic.com.au Tel : 212-983-1702, x212 Email : kprice@hfgcg.com Peter Dawson, CFO Tel: +61 3 9860 5700 Email: peter.dawson@metabolic.com.au
Metabolic Pharmaceuticals Ltd
CONTACT: Roland Scollay, CEO, +61-3-9860-5700,roland.scollay@metabolic.com.au or Peter Dawson, CFO, +61-3-9860-5700,peter.dawson@metabolic.com.au, both of Metabolic Pharmaceuticals Limited;or US Investors, Kathy Price of The Global Consulting Group,+1-212-983-1702, ext 212, kprice@hfgcg.com
Web site: http://www.metabolic.com.au/
